Sangamo Therapeutics (SMGO) earns FDA Fast Track Designation for SB-318 And SB-913 in treatment of Mucopolysaccharidosis (MPS) I and II

Source Link:

https://www.thestreet.com/story/14228295/1/sangamo-receives-fast-track-designation-from-the-fda-for-sb-318-and-sb-913-in-vivo-genome-editing-product-candidates-for-the-treatment-of-mps-i-and-mps-ii.html